Anti-CD19, Dual Co-stimulatory (4-1BB, CD3ζ) Chimeric Antigen Receptor T-cells in Patients With Relapsed/Refractory Aggressive Lymphoma or Acute Lymphoblastic Leukemia (ALL) (ACIT001/EXC002)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03938987|
Recruitment Status : Recruiting
First Posted : May 6, 2019
Last Update Posted : April 4, 2023
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
|Condition or disease||Intervention/treatment||Phase|
|Relapsed Non Hodgkin Lymphoma Relapsed Adult ALL Relapsed Pediatric ALL||Biological: autologous CD19-directed chimeric antigen receptor (CAR) T-cells||Phase 1 Phase 2|
Anti-CD19/4-1BB/CD3ζ CAR T-cell: autologous, unselected CD3+ lymphocytes collected from whole blood or apheresis, transfected with a lentiviral vector containing a 2nd generation chimeric antigen receptor (CAR) consisting of a scFv recognizing CD19 and dual co-stimulatory intracellular signaling domains (4-1BB and CD3ζ). All patients will receive lymphodepleting, conditioning chemotherapy in the form of cyclophosphamide (500 mg/m2/day) and fludarabine (30 mg/m^2/day) on Days -5, -4, and -3 prior to a CAR T-cell intravenous, single dose administration on Day 0.
Phase 1b: Dose Finding/Escalation Dose Level 1: 0.5 x 10^6/kg Dose Level 2: 1.0 x 10^6/kg Dose Level 3: 2.0 x 10^6/kg
Phase 2: Expansion Patients will receive lymphodepleting chemotherapy as indicated prior to receiving the CAR T-cell intravenous, single dose administration on Day 0 at the RP2D as identified during Phase 1b.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||63 participants|
|Intervention Model:||Single Group Assignment|
|Intervention Model Description:||All enrolled patients will be included in the safety and PK analyses. All patients receiving the dose and schedule selected for expansion will be included in the efficacy and futility analyses including patients who received the selected dose and schedule in the phase 1b dose selection and dose escalation. Analysis of during phase 2 will occur using a Simon 2-stage design.|
|Masking:||None (Open Label)|
|Official Title:||A Phase 1b/2 Multi-center, De-centralized, Dose Selection Study of Autologous CD19-directed Chimeric Antigen Receptor (CAR) T-cells in Patients With Relapsed/Refractory Aggressive Lymphoma or Acute Lymphoblastic Leukemia (ALL)|
|Actual Study Start Date :||March 3, 2021|
|Estimated Primary Completion Date :||June 2023|
|Estimated Study Completion Date :||December 2025|
Experimental: CAR T cells
Patients with relapsed/refractory B-cell ALL or NHL.
Biological: autologous CD19-directed chimeric antigen receptor (CAR) T-cells
Anti-CD19/4-1BB/CD3ζ CAR T-cell: autologous, unselected CD3+ lymphocytes collected from whole blood or apheresis, transfected with a lentiviral vector containing a 2nd generation chimeric antigen receptor (CAR) consisting of a scFv recognizing CD19 and dual co-stimulatory intracellular signaling domains (4-1BB and CD3ζ). All patients will receive lymphodepleting, conditioning chemotherapy in the form of cyclophosphamide (500 mg/m2/day) and fludarabine (30 mg/m2/day) on Days -5, -4, and -3 prior to a CAR T-cell intravenous, single dose administration on Day 0.
- Number and type of treatment-related adverse events. [ Time Frame: 3 years ]
- Number of dose limiting toxicities of anti-CD19 CAR T-cells [ Time Frame: 3 years ]
- Maximum concentration (Cmax). [ Time Frame: 3 years ]
- Time to maximum concentration (Tmax). [ Time Frame: 3 years ]
- Area-Under-the-Concentration-vs-time curve (AUC) in peripheral blood and/or bone marrow. [ Time Frame: 3 years ]
- Overall objective response rate (ORR: proportion of patients with confirmed responses of complete [CR] or partial [PR]) [ Time Frame: 3 years ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||2 Years to 70 Years (Child, Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
- Have given written informed consent prior to any study-specific procedures; children (defined as 17 years of age or less) require guardian consent.
- Eastern Cooperative Oncology Group (ECOG) Performance Status 0-2; or Karnofsky > 50%.
- Age of 2 to 70 years at time of screening.
- A histologically or cytologically documented, CD19+ non-hodgkin's lymphoma or ALL.
- At least 1 measurable lesion or FDG-avid disease by positron-emission tomography/computed tomography (PET/CT) for lymphoma patients; quantifiable evidence of ALL in either peripheral blood or bone marrow aspirate.
- Tumor tissue (archival or recent acquisition) must be available for correlative laboratory studies (such as immunohistochemistry, and others).
- At least 2 prior systemic therapies and patient must not be eligible for potentially curative standard-of-care therapy.
- Adequate renal function (defined as Cockroft-Gault creatinine clearance > 50 mL/min) and hepatic function (total bilirubin < 1.5x ULN; and AST/ALT < 3x ULN) unless directly related to malignant disease being treated for on study as demonstrated either by PET/CT imaging or by biopsy and histopathologic confirmation.
- For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods that result in a failure rate of < 1% per year during the treatment period and for at least 90 days after the last dose of study treatment. A woman is considered to be of childbearing potential if she is postmenarcheal, has not reached a postmenopausal state (≥ 12 continuous months of amenorrhea with no identified cause other than menopause), and has not undergone surgical sterilization (removal of ovaries and/or uterus). Examples of contraceptive methods with a failure rate of < 1% per year include bilateral tubal ligation, male sterilization, established proper use of hormonal contraceptives that inhibit ovulation, hormone-releasing intrauterine devices, and copper intrauterine devices. The reliability of sexual abstinence should be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not acceptable methods of contraception.
- Male participants should agree to not donate sperm during study period (i.e. up to 2 years following CAR T-cell administration).
- Male participants with reproductive potential must agree to use medical approved contraceptives during the study and for 90 days following the last dose of study treatment.
- Are reliable and willing to make themselves available for the duration of the study, and are willing to follow study procedures.
- Prior treatment with immunotherapy directly targeting T-cells (except anti-thymocyte globulin [ATG]), CD19-directed antibody-based therapies (except blinatumomab), or other gene therapy products.
- Received any investigational drug/anti-cancer therapy within 30 days.
- Concurrent participation in another therapeutic clinical trial.
- Therapeutic doses of corticosteroids (defined as > 20 mg/day prednisone or equivalent) within 7 days prior to blood collection for CAR T-cell product manufacture.
- Donor lymphocyte infusion (DLI) within 4 weeks prior to leukapheresis.
- Salvage or debulking chemotherapy within 1 week prior to blood collection for CAR T-cell product manufacture.
- Prior central nervous system (CNS) involvement.
- Unresolved acute toxicity of National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v4.03 Grade >1 (or baseline, whichever is greater) from prior anticancer therapy. Alopecia and other nonacute toxicities are acceptable.
- An uncontrolled intercurrent illness including but not limited to ongoing or active infection (including fever within 48 hours of screening), symptomatic congestive heart failure (i.e., New York Heart Association [NYHA] Class 3 or 4), unstable angina pectoris, clinically significant and uncontrolled cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
- Major surgical procedure within 30 days.
- Known history of human immunodeficiency virus (HIV) or active infection requiring therapy, or positive tests for hepatitis B surface antigen or hepatitis C ribonucleic acid (RNA).
- Any vaccination against infectious diseases (e.g., influenza, varicella) within 4 weeks (28 days) of initiation of study treatment.
- A woman who is pregnant or breastfeeding.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03938987
|Contact: Zack Breckenridgeemail@example.com|
|Foothills Medical Centre||Not yet recruiting|
|Calgary, Alberta, Canada, T2N2T9|
|Contact: Dr. Andrew Daly, MD|
|Tom Baker Cancer Centre||Not yet recruiting|
|Calgary, Alberta, Canada, T2N4N2|
|Contact: Dr. Peter Duggan, MD|
|Alberta Children's Hospital||Not yet recruiting|
|Calgary, Alberta, Canada, T3B6A8|
|Contact: Dr. Victor Lewis, MD|
|Cross Cancer Institute||Recruiting|
|Edmonton, Alberta, Canada, T6G1Z2|
|Contact: Dr. Michael P Chu, MD|
|Stollery Children's Hospital||Not yet recruiting|
|Edmonton, Alberta, Canada, T6G2B7|
|Contact: Dr. Sunil Desai, MD|
|University of Alberta Hospital||Recruiting|
|Edmonton, Alberta, Canada, T6G2B7|
|Contact: Dr. Peng Wang, MD|
|Principal Investigator:||Dr. Michael P Chu, MD||Cross Cancer Institute|
|Responsible Party:||University of Alberta|
|Other Study ID Numbers:||
|First Posted:||May 6, 2019 Key Record Dates|
|Last Update Posted:||April 4, 2023|
|Last Verified:||March 2023|
|Individual Participant Data (IPD) Sharing Statement:|
|Plan to Share IPD:||No|
|Studies a U.S. FDA-regulated Drug Product:||No|
|Studies a U.S. FDA-regulated Device Product:||No|
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Neoplasms by Histologic Type
Immune System Diseases